Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) DehydraTECH Featured in Human CBD Study Results Published in Clinical Journal
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, announced that final study results of a 2018 clinical study evaluating the use of its proprietary drug-delivery system have been published (http://ibn.fm/AYzRL) (http://ibn.fm/PfnAA). Published in Advances in Therapy, a peer-reviewed medical journal, the human clinical study evaluated CBD delivery and effectiveness using LXRP-patented, DehydraTECH(TM)-powered TurboCBD(TM) capsules. Key findings highlighted in the publication included the following: CBD in-plasma levels with the TurboCBD 90 mg dose were significantly higher than with the generic 90 mg dose at both 90 and 120 minutes (p < 0.05); Only the TurboCBD 90 mg…